A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

Ishibashi Hideyasu0 个研究点目标入组 126 人开始时间: 2022年10月21日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
•- Is not a woman of childbearing potential (WOCBP) or
•- Is a WOCBP and using a contraceptive method that is highly effective with a failure rate of less than (<)1 percent ([%] per year), during the intervention period and for specified time after end of study treatment.
•- A WOCBP must have a negative highly sensitive pregnancy test within 24-48 hours before the first dose of study intervention.
•-Histological or cytological documentation of loco-regionally recurrent solid tumors where curative treatment options have been exhausted, or metastatic solid tumors; types as follows:
•- head and neck squamous cell carcinoma (HNSCC)
•- non-small-cell lung cancer (NSCLC)
•- breast cancer (BC)
•- clear cell renal cell cancer (ccRCC)
•- gastric cancer (GC)
•- colorectal cancer (CRC)
•- endometrial cancer (EC)
•- ovarian epithelial cancer (OEC)
•-Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists.
•-Measurable disease per RECIST 1.1.
•-Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
•-Life expectancy of at least 12 weeks.
•-Adequate organ function, as defined in the protocol.

•-Prior treatment with the following therapies (specified time periods are from last dose of prior treatment to first dose of GSK4381562):
•- Any therapy directed against Polio virus receptor (PVR)-related immunoglobulin domain-containing (PVRIG) (COM701 or other anti-PVRIG monoclonal antibody [mAb]) or other cluster of differentiation (CD)226 axis receptor (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain [TIGIT] or CD96) at any time.
•- Other prior immunotherapy, chemotherapy, targeted therapy, biological therapy or radiation therapy within specified periods as defined in the protocol.
•- Investigational therapy: if the participant has participated in a clinical study and has received an investigational product within 4 weeks or 5 half-lives of the investigational product (whichever is shorter).
•-Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation.
•-Toxicity from previous anticancer treatment, including:
•- Greater than or equal to Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or
•- Toxicity related to prior treatment that has not resolved to less than or equal to (<=)Grade 1. Non clinically relevant Grade 2 toxicities, not constituting a safety risk by investigator judgment are allowed.
•-Participant has a known additional malignancy that progressed or required active treatment within the last 2 years.

发起方

Ishibashi Hideyasu